Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

65
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
65
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

68
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
68
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

47
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
47
Imaging Studies V: Intravenous Urography and Retrograde Pyelography01:22

Imaging Studies V: Intravenous Urography and Retrograde Pyelography

254
IntroductionIntravenous Urography (IVU) and Retrograde Pyelography (RP) are important diagnostic imaging techniques used to evaluate the urinary system. These methods help identify structural abnormalities, obstructions, and functional issues in the kidneys, ureters, and bladder. Both procedures use iodine-based contrast media to enhance the visibility of urinary tract structures on X-ray images, though they differ in their methods and indications.1. Intravenous Urography (IVU)Intravenous...
254
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

117
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
117
Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

200
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incremental Cancer Detection and False-Positive Burden of Screening Ultrasound After Negative Digital Breast Tomosynthesis: A 10-Year, 100,000-Examination Retrospective Study.

Academic radiology·2026
Same author

Isolated Axillary Lymphadenopathy in Women Without a Known Breast Cancer Diagnosis: A Multicenter Study of Biopsy Outcomes.

AJR. American journal of roentgenology·2026
Same author

Toward creating "caninized" mice: reconstitution of canine immune cells in immunodeficient mice.

American journal of veterinary research·2026
Same author

Migraine in women undergoing fertility treatment: A prospective study.

Headache·2026
Same author

Evaluating the Impact of Respiratory Pathogen Testing on Pediatric Emergency Department Return Visits and Management.

Pediatric emergency care·2026
Same author

Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.

Rheumatology advances in practice·2026

Related Experiment Video

Updated: Oct 6, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive

Vanessa Bellat1, Adam O Michel2, Charlene Thomas3

  • 1Department of Radiology, Molecular Imaging Innovations Institute, Weill Cornell Medicine, New York, New York.

Cancer Research
|January 18, 2022
PubMed
Summary

A novel urinary drug-disposing approach uses peptides to deliver cancer drugs noninvasively to treat nonmuscle invasive bladder cancer (NMIBC). This method improves survival and tumor suppression compared to traditional intravesical therapy.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K

Related Experiment Videos

Last Updated: Oct 6, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Drug Delivery Systems

Background:

  • Nonmuscle invasive bladder cancer (NMIBC) treatment relies on transurethral resection and intravesical therapy (IT), which has high recurrence rates and limitations.
  • Intravesical therapy is invasive, painful, and fails to treat upper urinary tract tumors, leading to poor patient compliance and quality of life.
  • There is a critical need for effective, noninvasive treatments for NMIBC and related urinary system cancers.

Purpose of the Study:

  • To develop a novel urinary drug-disposing (UDD) approach for improved NMIBC treatment.
  • To utilize the rapid renal clearance of peptides as a carrier for targeted drug delivery to the urinary system.
  • To assess the efficacy and safety of the UDD approach in preclinical models.

Main Methods:

  • A 12-amino acid bio-inert peptide (Bdd) was engineered for exclusive renal filtration and drug delivery.
  • The microtubule inhibitor DM1 was conjugated to the peptide carrier for targeted delivery to NMIBC.
  • The UDD approach was administered intravenously in mice with human bladder tumors and compared to intravesical therapy (mitomycin) and free DM1.

Main Results:

  • The UDD approach significantly prolonged survival in mice with bladder tumors.
  • Intravenous UDD treatment was more effective at suppressing tumor growth than intravesical mitomycin.
  • The UDD approach demonstrated improved safety compared to free DM1, with minimal off-target accumulation.

Conclusions:

  • Rapid renal clearance of peptides can be leveraged for targeted cancer therapy in the urinary system.
  • The UDD approach offers a potent, noninvasive, and safer alternative to current NMIBC treatments.
  • This strategy holds promise for treating bladder cancer and potentially other urinary tract tumors, including kidney tumors.